Progress in Discovery and Evaluation of Treatments to Prevent Bronchopulmonary Dysplasiavan Marter L.J.
Children’s Hospital, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: Recent improvements in the survival of extremely preterm infants have been accompanied by evolution in the pathogenesis and histopathology of bronchopulmonary dysplasia (BPD). Although oxygen and barotrauma-induced injury remain important contributing factors, pulmonary developmental arrest appears to play an equally important causal role in prolonged respiratory illness, especially among the most immature surviving preterm newborns. To date, clinical trials have failed to demonstrate a substantial benefit of a single treatment or preventive strategy for BPD. Objectives: To evaluate the current evidence in favor of treatments that might prevent BPD. Methods: Review of clinical studies of preventive treatment strategies for BPD. Results: High frequency oscillatory ventilation, permissive hypercapnea, and inhaled nitric oxide might offer benefit to infants at risk of BPD. These and other potential preventive therapies for BPD, such as superoxide dismutase, inositol, and α1-proteinase inhibitor, deserve further study. Conclusions: Although some current treatments offer promise, no preventive therapy for BPD has proven safe and effective, except for intramuscular vitamin A. Additional studies of respiratory technologies, management strategies, and protective molecules are needed.
© 2006 S. Karger AG, Basel
- Northway WH Jr, Rosan RC, Porter DY: Pulmonary disease following respirator therapy of hyaline-membrane disease: bronchopulmonary dysplasia. N Engl J Med 1967;276:357–368.
- Horbar JD, Badger GJ, Carpenter JH, Fanaroff AA, Kilpatrick S, LaCorte M, Phibbs R, Soll RF: Trends in mortality and morbidity for very low birth weight infants, 1991–1999. Pediatrics 2002;110:143–151.
- Fanaroff AA, Hack M, Walsh MC: The NICHD neonatal research network: changes in practice and outcomes during the first 15 years. Semin Perinatol 2003;27:281–287.
- Srisuparp P, Marks JD, Khoshnood B, Schreiber MD: Predictive power of initial severity of pulmonary disease for subsequent development of bronchopulmonary dysplasia. Biol Neonate 2003;84:31–36.
- Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ, Richardson DK: Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. J Pediatr 2005;146:469–473.
- Christou H, Brodsky D: Lung injury and bronchopulmonary dysplasia in newborn infants. J Intens Care Med 2005;20:76–87.
- Bhatt AJ, Amin SB, Chess PR, Watkins RH, Maniscalco WM: Expression of vascular endothelial growth factor and Flk-1 in developing and glucocorticoid-treated mouse lung. Pediatr Res 2000;47:606–613.
- Coalson JJ, Winter VT, Siler-Khodr T, Yoder BA: Neonatal chronic lung disease in extremely immature baboons. Am J Respir Crit Care Med 1999;160:1333–1346.
- Lyon A: Chronic lung disease of prematurity: the role of intra-uterine infection. Eur J Pediatr 2000;159:798–802.
- Speer CP: Inflammation and bronchopulmonary dysplasia. Semin Neonatol 2003;8:29–38.
Romero R, Chaiworapongsa T, Espinoza J: Micronutrients and intrauterine infection, preterm birth and the fetal inflammatory response syndrome. J Nutr 2003;133:1668S–1673S.
- Watterberg KL, Demers LM, Scott SM, Murphy S: Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996;97:210–215.
- Schmidt B, Cao L, Mackensen-Haen S, Kendziorra H, Klingel K, Speer CP: Chorioamnionitis and inflammation of the fetal lung. Am J Obstet Gynecol 2001;185:173–177.
- Matsuda T, Nakajima T, Hattori S, Hanatani K, Fukazawa Y, Kobayashi K, Fujimoto S: Necrotizing funisitis: clinical significance and association with chronic lung disease in premature infants. Am J Obstet Gynecol 1997;177:1402–1407.
- Kim CJ, Yoon BH, Park SS, Kim MH, Chi JG: Acute funisitis of preterm but not term placentas is associated with severe fetal inflammatory response. Hum Pathol 2001;32:623–629.
- Yoon BH, Romero R, Kim KS, Park JS, Ki SH, Kim BI, Jun JK: A systemic fetal inflammatory response and the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 1999;181:773–779.
- Viscardi RM, Muhumuza CK, Rodriguez A, Fairchild KD, Sun CC, Gross GW, Campbell AB, Wilson PD, Hester L, Hasday JD: Inflammatory markers in intrauterine and fetal blood and cerebrospinal fluid compartments are associated with adverse pulmonary and neurologic outcomes in preterm infants. Pediatr Res 2004;55:1009–1017.
- Ghezzi F, Gomez R, Romero R, Yoon BH, Edwin SS, David C, Janisse J, Mazor M: Elevated interleukin-8 concentrations in amniotic fluid of mothers whose neonates subsequently develop bronchopulmonary dysplasia. Eur J Obstet Gynecol Reprod Biol 1998;78:5–10.
- Yoon BH, Romero R, Park JS, Kim CJ, Kim SH, Choi JH, Han TR: Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years. Am J Obstet Gynecol 2000;182:675–681.
- Kotecha S, Wilson L, Wangoo A, Silverman M, Shaw RJ: Increase in interleukin (IL)-1 beta and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity. Pediatr Res 1996;40:250–256.
- Beresford MW, Shaw NJ: Detectable IL-8 and IL-10 in bronchoalveolar lavage fluid from preterm infants ventilated for respiratory distress syndrome. Pediatr Res 2002;52:973–978.
- Munshi UK, Niu JO, Siddiq MM, Parton LA: Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. Pediatr Pulmonol 1997;24:331–336.
- Baier RJ, Majid A, Parupia H, Loggins J, Kruger TE: CC chemokine concentrations increase in respiratory distress syndrome and correlate with development of bronchopulmonary dysplasia. Pediatr Pulmonol 2004;37:137–148.
- Albertine KH, Jones GP, Starcher BC, Bohnsack JF, Davis PL, Cho SC, Carlton DP, Bland RD: Chronic lung injury in preterm lambs: disordered respiratory tract development. Am J Respir Crit Care Med 1999;159:945–958.
- Kallapur SG, Jobe AH, Ikegami M, Bachurski CJ: Increased IP-10 and MIG expression after intra-amniotic endotoxin in preterm lamb lung. Am J Respir Crit Care Med 2003;167:779–786.
- Van Marter LJ, Dammann O, Allred EN, Leviton A, Pagano M, Moore M, Martin C: Chorioamnionitis, mechanical ventilation, and postnatal sepsis as modulators of chronic lung disease in preterm infants. J Pediatr 2002;140:171–176.
- Ikegami M, Kallapur SG, Jobe AH: Initial responses to ventilation of premature lambs exposed to intra-amniotic endotoxin 4 days before delivery. Am J Physiol 2004;286:L573–579.
- Donn SM, Sinha SK: Can mechanical ventilation strategies reduce chronic lung disease? Semin Neonatol 2003;8:441–448.
- Avery ME, Tooley WH, Keller JB, Hurd SS, Bryan MH, Cotton RB, Epstein MF, Fitzhardinge PM, Hansen CB, Hansen TN: Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics 1987;79:26–30.
Stevens TP, Blennow M, Soll RF: Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 2004:CD003063.
De Paoli AG, Davis PG, Faber B, Morley CJ: Devices and pressure sources for administration of nasal continuous positive airway pressure (NCPAP) in preterm neonates. Cochrane Database Syst Rev 2002:CD002977.
- De Klerk AM, De Klerk RK: Nasal continuous positive airway pressure and outcomes of preterm infants. J Paediatr Child Health 2001;37:161–167.
- Narendran V, Donovan EF, Hoath SB, Akinbi HT, Steichen JJ, Jobe AH: Early bubble CPAP and outcomes in ELBW preterm infants. J Perinatol 2003;23:195–199.
- Finer NN, Carlo WA, Duara S, Fanaroff AA, Donovan EF, Wright LL, Kandefer S, Poole WK: Delivery room continuous positive airway pressure/positive end-expiratory pressure in extremely low birth weight infants: a feasibility trial. Pediatrics 2004;114:651–657.
- Thomson MA, Yoder BA, Winter VT, Martin H, Catland D, Siler-Khodr TM, Coalson JJ: Treatment of immature baboons for 28 days with early nasal continuous positive airway pressure. Am J Respir Crit Care Med 2004;169:1054–1062.
- Mariani G, Cifuentes J, Carlo WA: Randomized trial of permissive hypercapnia in preterm infants. Pediatrics 1999;104:1082–1088.
Woodgate PG, Davies MW: Permissive hypercapnia for the prevention of morbidity and mortality in mechanically ventilated newborn infants. Cochrane Database Syst Rev 2001:CD002061.
- Carlo WA, Stark AR, Wright LL, Tyson JE, Papile LA, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S, Poole WK, Stoll B: Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. J Pediatr 2002;141:370–374.
- Strand M, Ikegami M, Jobe AH: Effects of high PCO2 on ventilated preterm lamb lungs. Pediatr Res 2003;53:468–472.
McCallion N, Davis PG, Morley CJ: Volume-targeted versus pressure-limited ventilation in the neonate. Cochrane Database Syst Rev 2005:CD003666.
- Courtney SE, Durand DJ, Asselin JM, Hudak ML, Aschner JL, Shoemaker CT: High-frequency oscillatory ventilation versus conventional mechanical ventilation for very-low-birth-weight infants. N Engl J Med 2002;347:643–652.
- Johnson AH, Peacock JL, Greenough A, Marlow N, Limb ES, Marston L, Calvert SA: High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. N Engl J Med 2002;347:633–642.
- Van Reempts P, Borstlap C, Laroche S, Van der Auwera JC: Early use of high frequency ventilation in the premature neonate. Eur J Pediatr 2003;162:219–226.
- Stark AR: High-frequency oscillatory ventilation to prevent bronchopulmonary dysplasia – are we there yet? N Engl J Med 2002;347:682–684.
Henderson-Smart DJ, Bhuta T, Cools F, Offringa M: Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. Cochrane Database Syst Rev 2003:CD000104.
Bhuta T, Henderson-Smart DJ: Elective high frequency jet ventilation versus conventional ventilation for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2000:CD000328.
- Thome UH, Carlo WA, Pohlandt F: Ventilation strategies and outcome in randomised trials of high frequency ventilation. Arch Dis Child Fetal Neonatal Ed 2005;90:F466–473.
- El Kebir D, Taha R, Hubert B, Gauvin D, Gangal M, Blaise G: The anti-inflammatory effect of inhaled nitric oxide on pulmonary inflammation in a swine model. Can J Physiol Pharmacol 2005;83:252–258.
- El Kebir D, Hubert B, Taha R, Troncy E, Wang T, Gauvin D, Gangal M, Blaise G: Effects of inhaled nitric oxide on inflammation and apoptosis after cardiopulmonary bypass. Chest 2005;128:2910–2917.
- Kang JL, Park W, Pack IS, Lee HS, Kim MJ, Lim CM, Koh Y: Inhaled nitric oxide attenuates acute lung injury via inhibition of nuclear factor-kappa B and inflammation. J Appl Physiol 2002;92:795–801.
- Kinsella JP, Parker TA, Galan H, Sheridan BC, Halbower AC, Abman SH: Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr Res 1997;41:457–463.
- Kobayashi H, Hataishi R, Mitsufuji H, Tanaka M, Jacobson M, Tomita T, Zapol WM, Jones RC: Antiinflammatory properties of inducible nitric oxide synthase in acute hyperoxic lung injury. Am J Respir Cell Mol Biol 2001;24:390–397.
- Razavi HM, Werhun R, Scott JA, Weicker S, Wang le F, McCormack DG, Mehta S: Effects of inhaled nitric oxide in a mouse model of sepsis-induced acute lung injury. Crit Care Med 2002;30:868–873.
- Shanley TP, Schmal H, Friedl HP, Jones ML, Ward PA: Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats. J Immunol 1995;154:4793–4802.
- Hamon I, Fresson J, Nicolas MB, Buchweiller MC, Franck P, Hascoet JM: Early inhaled nitric oxide improves oxidative balance in very preterm infants. Pediatr Res 2005;57:637–643.
- Kinsella JP, Walsh WF, Bose CL, Gerstmann DR, Labella JJ, Sardesai S, Walsh-Sukys MC, McCaffrey MJ, Cornfield DN, Bhutani VK, Cutter GR, Baier M, Abman SH: Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet 1999;354:1061–1065.
- The Franco-Belgium Collaborative NO Trial Group: Early compared with delayed nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet 1999;354:1066–1071.
- Subhedar NV, Ryan SW, Shaw NJ: Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Arch Dis Child Fetal Neonatal Ed 1997;77:F185–190.
Barrington KJ, Finer NN: Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2001:CD000509.
- Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P: Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003;349:2099–2107.
- Mestan KK, Marks JD, Hecox K, Huo D, Schreiber MD: Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med 2005;353:23–32.
- Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, Perritt R, Higgins RD, Oh W, Hudak ML, Laptook AR, Shankaran S, Finer NN, Carlo WA, Kennedy KA, Fridriksson JH, Steinhorn RH, Sokol GM, Konduri GG, Aschner JL, Stoll BJ, D’Angio CT, Stevenson DK: Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 2005;353:13–22.
- Martin RJ: Nitric oxide for preemies – not so fast. N Engl J Med 2003;349:2157–2159.
- Martin RJ, Walsh MC: Inhaled nitric oxide for preterm infants – who benefits? N Engl J Med 2005;353:82–84.
- Collard KJ, Godeck S, Holley JE, Quinn MW: Pulmonary antioxidant concentrations and oxidative damage in ventilated premature babies. Arch Dis Child Fetal Neonatal Ed 2004;89:F412–416.
- Kaarteenaho-Wiik R, Kinnula VL: Distribution of antioxidant enzymes in developing human lung, respiratory distress syndrome, and bronchopulmonary dysplasia. J Histochem Cytochem 2004;52:1231–1240.
- Zoban P, Cerny M: Immature lung and acute lung injury. Physiol Res 2003;52:507–516.
- Kao SJ, Wang D, Lin HI, Chen HI: N-acetylcysteine abrogates acute lung injury induced by endotoxin. Clin Exp Pharmacol Physiol 2006;33:33–40.
- Sandberg K, Fellman V, Stigson L, Thiringer K, Hjalmarson O: N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth weight infants. Biol Neonate 2004;86:275–279.
- Ahola T, Lapatto R, Raivio KO, Selander B, Stigson L, Jonsson B, Jonsbo F, Esberg G, Stovring S, Kjartansson S, Stiris T, Lossius K, Virkola K, Fellman V: N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. J Pediatr 2003;143:713–719.
- Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W: Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 2003;111:469–476.
- Chang LY, Subramaniam M, Yoder BA, Day BJ, Ellison MC, Sunday ME, Crapo JD: A catalytic antioxidant attenuates alveolar structural remodeling in bronchopulmonary dysplasia. Am J Respir Crit Care Med 2003;167:57–64.
- Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, Stoll BJ, Lemons JA, Stevenson DK, Bauer CR, Korones SB, Fanaroff AA: Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999;340:1962–1968.
Darlow BA, Graham PJ: Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev 2002:CD000501.
- McGowan S, Jackson SK, Jenkins-Moore M, Dai HH, Chambon P, Snyder JM: Mice bearing deletions of retinoic acid receptors demonstrate reduced lung elastin and alveolar numbers. Am J Respir Cell Mol Biol 2000;23:162–167.
Massaro GD, Massaro D: Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats. Am J Physiol 1996;270:L305–310.
- Bland RD, Albertine KH, Pierce RA, Starcher BC, Carlton DP: Impaired alveolar development and abnormal lung elastin in preterm lambs with chronic lung injury: potential benefits of retinol treatment. Biol Neonate 2003;84:101–102.
Howlett A, Ohlsson A: Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2003:CD000366.
Friedman CA, Temple DM, Robbins KK, Miller CJ, Rawson JE: Randomized controlled trial of high inositol and calorie supplementation in preterm infants at risk for chronic lung and eye disease. American Academy of Pediatrics Annual Meeting, 1995.
- Hallman M, Jarvenpaa AL, Pohjavuori M: Respiratory distress syndrome and inositol supplementation in preterm infants. Arch Dis Child 1986;61:1076–1083.
Hallman M, Bry K, Hoppu K, Lappi M, Pohjavuori M: Inositol supplementation in premature infants with respiratory distress syndrome N Engl J Med 1992;326:1233–1239.
- Merritt TA, Cochrane CG, Holcomb K, Bohl B, Hallman M, Strayer D, Edwards DK, 3rd, Gluck L: Elastase and alpha 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome: role of inflammation in the pathogenesis of bronchopulmonary dysplasia. J Clin Invest 1983;72:656–666.
- Ekekezie I, Thibeault DW, Simon SD, Norberg M, Merrill JD, Ballard RA, Ballard PL, Truog WE: Low levels of tissue inhibitors of metalloproteinases with a high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio are present in tracheal aspirate fluids of infants who develop chronic lung disease. Pediatrics 2004;113:1709–1714.
Dunn M, Stiskal J, O’Brien K, Ito S, Cox DW, Kelly E, Shennan A, NewmanC, Wylie L, Hanna K, Saunders G, Rabinowich M: Alfa-1 proteinase inhibitor (A1P1) therapy for the prevention of chronic lung disease of prematurity (CLD)-a dose ranging study and meta analysis with previous randomized clinical trial (RCT). Pediatr Res 2000:397A (2345).
- Stiskal JA, Dunn MS, Shennan AT, O’Brien KK, Kelly EN, Koppel RI, Cox DW, Ito S, Chappel SL, Rabinovitch M: Alpha1-proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity: a randomized, controlled trial. Pediatrics 1998;101:89–94.
Shah P, Ohlsson A: Alpha-1-proteinase inhibitor (a1PI) for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001:CD002775.
Danan C, Jarreau PH, Franco ML, Dassieu G, Grillon C, Abd Alsamad I, Lafuma C, Harf A, Delacourt C: Gelatinase activities in the airways of premature infants and development of bronchopulmonary dysplasia. Am J Physiol 2002;283:L1086–1093.
- Schulz CG, Sawicki G, Lemke RP, Roeten BM, Schulz R, Cheung PY: MMP-2 and MMP-9 and their tissue inhibitors in the plasma of preterm and term neonates. Pediatr Res 2004;55:794–801.
- Sluis KB, Darlow BA, Vissers MC, Winterbourn CC: Proteinase-antiproteinase balance in tracheal aspirates from neonates. Eur Respir J 1994;7:251–259.
- Sveger T, Ohlsson K, Polberger S, Noack G, Morse H, Laurin S: Tracheobronchial aspirate fluid neutrophil lipocalin, elastase- and neutrophil protease-4-alpha1-antitrypsin complexes, protease inhibitors and free proteolytic activity in respiratory distress syndrome. Acta Paediatr 2002;91:934–937.
- AAP Committee on Fetus and Newborn: Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002;109:330–340.
- Watterberg KL, Scott SM, Naeye RL: Chorioamnionitis, cortisol, and acute lung disease in very low birth weight infants. Pediatrics 1997;99:E6.
- Watterberg KL, Shaffer ML, Garland JS, Thilo EH, Mammel MC, Couser RJ, Aucott SW, Leach CL, Cole CH, Gerdes JS, Rozycki HJ, Backstrom C: Effect of dose on response to adrenocorticotropin in extremely low birth weight infants. J Clin Endocrinol Metab 2005;90:6380–6385.
- Watterberg KL, Gerdes JS, Gifford KL, Lin HM: Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 1999;104:1258–1263.
- Watterberg KL, Scott SM, Backstrom C, Gifford KL, Cook KL: Links between early adrenal function and respiratory outcome in preterm infants: Airway inflammation and patent ductus arteriosus. Pediatrics 2000;105:320–324.
- Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH, Mammel MC, Couser RJ, Garland JS, Rozycki HJ, Leach CL, Backstrom C, Shaffer ML: Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004;114:1649–1657.
- Peltoniemi O, Kari MA, Heinonen K, Saarela T, Nikolajev K, Andersson S, Voutilainen R, Hallman M: Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr 2005;146:632–637.
- Ballard PL, Gonzales LW, Godinez RI, Godinez MH, Savani RC, McCurnin DC, Gibson LL, Yoder BA, Kerecman JD, Grubb PH, Shaul PW: Surfactant composition and function in a primate model of infant chronic lung disease: effects of inhaled nitric oxide. Pediatr Res 2006;59:157–162.
Vozzelli MA, Mason SN, Whorton MH, Auten RL Jr: Antimacrophage chemokine treatment prevents neutrophil and macrophage influx in hyperoxia-exposed newborn rat lung. Am J Physiol 2004;286:L488–493.
- Chiba H, Piboonpocanun S, Mitsuzawa H, Kuronuma K, Murphy RC, Voelker DR: Pulmonary surfactant proteins and lipids as modulators of inflammation and innate immunity. Respirology 2006;11(suppl 1):S2–6.
- Levine CR, Gewolb IH, Allen K, Welch RW, Melby JM, Pollack S, Shaffer T, Pilon AL, Davis JM: The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. Pediatr Res 2005;58:15–21.
- Sunday ME, Shan L, Subramaniam M: Immunomodulatory functions of the diffuse neuroendocrine system: implications for bronchopulmonary dysplasia. Endocr Pathol 2004;15:91–106.
Shah P, Ohlsson A: Alpha-1-proteinase inhibitor (a1PI) for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2005:CD002775.
Suresh GK, Davis JM, Soll RF: Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants. Cochrane Database Syst Rev 2001:CD001968.
Shah V, Ohlsson A, Halliday HL, Dunn MS: Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2000:CD001969.
Shah SS, Ohlsson A, Halliday H, Shah VS: Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev 2003:CD002057.
Halliday HL, Ehrenkranz RA, Doyle LW: Early postnatal (<96 h) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003:CD001146.
Halliday HL, Ehrenkranz RA, Doyle LW: Moderately early (7–14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003:CD001144.
Halliday HL, Ehrenkranz RA, Doyle LW: Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003:CD001145.
Subramaniam P, Henderson-Smart DJ, Davis PG: Prophylactic nasal continuous positive airways pressure for preventing morbidity and mortality in very preterm infants. Cochrane Database Syst Rev 2005:CD001243.
Greenough A, Milner AD, Dimitriou G: Synchronized mechanical ventilation for respiratory support in newborn infants. Cochrane Database Syst Rev 2004:CD000456.
Henderson-Smart DJ, Bhuta T, Cools F, Offringa M: Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. Cochrane Database Syst Rev 2003:CD000104.
Barrington K, Finer N: Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2006:CD000509.
Mabanta CG, Pryhuber GS, Weinberg GA, Phelps DL: Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev 2003:CD003744.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.